A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
NCT07836270 on ClinicalTrials.gov · last registry update 2026-09-23
A small phase 3 — 192 participants, against a typical 424. Due to report 8 June 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Percent change in Body Mass Index (BMI). Sponsors move these dates routinely; any movement since this site started watching is listed below. ecnoglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- ecnoglutide
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 192
- Started
- 2026-10-31
- Primary completion
- 2028-06-08 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-23 | First seen in registry | Registered as NOT_YET_RECRUITING, P3 |
Primary outcome
Percent change in Body Mass Index (BMI)
Conditions studied
Adolescents With Obesity · Adolescents With Overweight & Weight-related Comorbidities
Every field above is taken directly from the registry record. See all detected changes across the class, or the ecnoglutide page for this molecule’s full trial and approval history.